Victoria A. Appleman

TL;DR: The identification of PF-06463922, a ROS1/anaplastic lymphoma kinase (ALK) inhibitor, with exquisite potency against ROS1 fusion kinases, capable of inhibiting the ROS1G2032R mutation and FIG-ROS1–driven glioblastoma tumor growth in preclinical models is reported.

TL;DR: It is found that transcriptional activation mediated by the Gli family of transcription factors, although dispensable for pancreatic development, is required for Kras-induced proliferation and survival in primary pancreatic epithelial cells in culture and forKras-driven pancreatic intraepithelial neoplasia and PDAC formation in vivo.

TL;DR: It is suggested that the WNT/β-catenin signaling pathway enhances pancreatic cancer development and malignancy in part via up-regulation of CYR61.

TL;DR: It is shown that KRASG12D and BRAFV600E enhance PDEC proliferation and increase survival after exposure to apoptotic stimuli in a manner dependent on MEK/ERK and PI3K/AKT signaling, and a novel mechanism of PI3k/AKt activation downstream of activated KRAS is identified.

TL;DR: It is reported that malignant pleural mesothelioma cells robustly express STING and are responsive to STING agonist treatment ex vivo, and the fundamental importance of using human tumor samples to assess innate and cellular immune therapies is revealed.